New Method Makes Measuring Cell Squishiness and Stiffness Faster, Easier, and More Reliable

In a groundbreaking advancement poised to reshape cellular diagnostics, researchers at Brown University, in collaboration with the National Institute of Standards and Technology (NIST), have unveiled a revolutionary microfluidic platform capable of accurately assessing the mechanical properties of individual cells. This new technology, known as the mechanophenotyping cytometer, promises to unlock vital insights into the elasticity of cells—a biomarker intricately linked with disease progression, diagnosis, and prognosis across a myriad of conditions.

Traditionally, probing the biomechanical characteristics of cells has relied on atomic force microscopy (AFM), a meticulous technique involving the mechanical indentation of individual cells adhered to surfaces. While AFM has been revered as the gold standard due to its precision, it suffers from severe limitations—it is time-consuming, examining cells one at a time, and its measurements can vary significantly depending on the exact site of indentation, making high-throughput analysis almost impossible. For instance, AFM operators typically evaluate one cell every 30 seconds, severely restricting population-level assessments needed for comprehensive biological interpretations.

The Brown-NIST team circumvented these limitations by ingeniously harnessing the principle of “time-of-flight” (TOF) within microfluidic channels. By channeling cells through precisely calibrated fluidic environments and recording the transit times between defined checkpoints, they developed a rapid, label-free approach to infer cellular stiffness. Conceptually, softer cells deform and align toward the center of the flow channel, where fluid velocity peaks, thereby exhibiting shorter transit times, while stiffer cells remain near channel walls where fluid flow is slower, resulting in longer transit durations.

This innovative method exploits the inherent fluid dynamics within microchannels and leverages fluorescence signals to assess cell size concurrently, crucial for normalizing mechanical readings. By integrating size measurements and TOF data, the researchers derived an elastic modulus—a quantitative metric describing a cell’s deformability and mechanical rigidity—vastly expanding throughput capabilities to hundreds or thousands of cells per second.

Lead author Graylen Chickering, a Ph.D. candidate specializing in biomedical engineering, emphasized the transformative potential of mechanophenotyping cytometry. “Our technology allows for rapid, multidimensional mechanical fingerprinting of cells without the bottlenecks associated with traditional modalities like AFM,” Chickering explained. “This not only accelerates data acquisition tremendously but also preserves the subtle heterogeneities within large cellular populations, which are often lost or ignored in conventional assays.”

A compelling biological motivation underpins this technological development. Cell mechanical phenotypes are increasingly recognized as dynamic reporters of pathological states. Cancer cells, as tumors progress, generally soften—a mechanical signature that correlates with invasive potential and metastatic risk. Conversely, red blood cells afflicted by disorders such as malaria or sickle cell anemia exhibit increased stiffness, impairing their circulatory function. Beyond oncology and hematology, altered cellular mechanics emerge in neurodegenerative conditions, cardiovascular disorders, and chronic inflammatory diseases, underscoring the diagnostic breadth this cytometer could offer.

Eric Darling, an associate professor involved in the project, underscored the method’s reproducibility and accuracy. “Our validation data using synthetic polymer particles precisely mimicking cellular size and stiffness demonstrated excellent alignment between theoretical expectations and observed TOF differences,” he noted. “Such robustness is critical for clinical translation, where diagnostic consistency must be rigorously maintained.”

The integration of polymeric cell mimics was pivotal for method calibration and error quantification. Brown’s Institute for Biology, Engineering, and Medicine contributed these synthetic analogs, tailored with defined elastic moduli and sizes, enabling systematic benchmarking of the cytometer’s measurements. Meanwhile, NIST’s design innovation offered multiple independent measurement regions within the device, allowing parallel acquisition of data points that quantify biological variability and technical noise, thereby bolstering the fidelity of mechanical phenotyping.

This synergy of engineering and biology has created a tool with far-reaching implications. Prospective studies are already in planning phases to analyze mechanical phenotypes of cells extracted from clinical samples, aiming to delineate mechanical deviations between healthy and diseased states—particularly in cancers, where early detection and prognosis hinge on nuanced cellular behavior.

Beyond diagnostic utility, this technology opens avenues for fundamental research into mechanobiology. The capacity to rapidly quantify cell stiffness in diverse physiological and pathological contexts could illuminate mechanotransduction pathways and cellular response mechanisms to biochemical stimuli, advancing the broader understanding of cell biology.

The mechanophenotyping cytometer represents a pivotal leap from labor-intensive, low-throughput mechanical measurements to a scalable, high-throughput platform compatible with existing fluorescence cytometry infrastructures. This harmonization facilitates seamless integration into biomedical workflows, accelerating adoption in research and clinical laboratories.

In sum, the Brown-NIST collaboration has realized a microfluidic cytometer capable of decoding the mechanical language of cells with unprecedented speed and precision. As mechanophenotyping transitions from experimental proof-of-concept to practical diagnostic adjunct, it holds the promise to become a cornerstone technology in personalized medicine—offering real-time assessments that empower clinicians and researchers to detect, monitor, and understand disease with a depth of mechanical insight previously unattainable.

Funding for this pioneering work was generously provided by the U.S. National Science Foundation and the National Institute of Standards and Technology, reflecting the strategic importance of interdisciplinary scientific endeavors that seamlessly bridge engineering ingenuity and biological complexity.

News Publication Date: 21-Apr-2026

Web References: DOI: 10.1039/D5LC00930H

Keywords

Cell structure, Cell biology, Cellular physiology, Bioengineering